Current industrial practices of assessing permeability and P-glycoprotein interaction

Combination of the in vitro models that are high throughput but less predictive and the in vivo models that are low throughput but more predictive is used effectively to evaluate the intestinal permeability and transport characteristics of a large number of drug candidates during lead selection and lead optimization processes. Parallel artificial membrane permeability assay and Caco-2 cells are the most frequently used in vitro models to assess intestinal permeability. The popularity of these models stems from their potential for high throughput, cost effectiveness, and adequate predictability of absorption potential in humans. However, several caveats associated with these models (eg, poor predictability for transporter-mediated and paracellularly absorbed compounds, significant nonspecific binding to cells/devices leading to poor recovery, variability associated with experimental factors) need to be considered carefully to realize their full potential. P-glycoprotein, among other pharmaceutically relevant transporters, has been well demonstrated to be the major determinant of drug disposition. The review article presents an objective analysis of the permeability and transporter models currently being used in the pharmaceutical industry and could help guide the discovery scientists in implementing these models in an optimal fashion.

[1]  J. Dressman,et al.  Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women , 1990, Pharmaceutical Research.

[2]  T. Kissel,et al.  Heterogeneity in the human intestinal cell line Caco-2 leads to differences in transepithelial transport , 1995 .

[3]  Jiunn H. Lin,et al.  Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. , 2003, Advanced drug delivery reviews.

[4]  B. Aungst,et al.  The Influence of Donor and Reservoir Additives on Caco-2 Permeability and Secretory Transport of HIV Protease Inhibitors and Other Lipophilic Compounds , 2000, Pharmaceutical Research.

[5]  S. Chong,et al.  A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. , 2005, International journal of pharmaceutics.

[6]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[7]  K. Brouwer,et al.  Secretory Transport of Ranitidine and Famotidine across Caco-2 Cell Monolayers , 2002, Journal of Pharmacology and Experimental Therapeutics.

[8]  S. Binkley,et al.  Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. , 1999, The Journal of pharmacology and experimental therapeutics.

[9]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[10]  P. Artursson Cell cultures as models for drug absorption across the intestinal mucosa. , 1991, Critical reviews in therapeutic drug carrier systems.

[11]  A. Ungell Caco-2 replace or refine? , 2004, Drug discovery today. Technologies.

[12]  A. Avdeef,et al.  Physicochemical profiling (solubility, permeability and charge state). , 2001, Current topics in medicinal chemistry.

[13]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[14]  A. Avdeef,et al.  PAMPA--a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa(flux)--optimized design (pOD-PAMPA). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  M. Morris,et al.  Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. , 2004, Molecular pharmacology.

[16]  R A Morrison,et al.  Current methodologies used for evaluation of intestinal permeability and absorption. , 2000, Journal of pharmacological and toxicological methods.

[17]  Ryuichi Matsuno,et al.  Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. , 2004, Bioorganic & medicinal chemistry.

[18]  E. Kerns,et al.  High throughput physicochemical profiling for drug discovery. , 2001, Journal of pharmaceutical sciences.

[19]  T. Kissel,et al.  Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. , 2004, Journal of pharmaceutical sciences.

[20]  A. Herrmann,et al.  Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). , 2003, The Biochemical journal.

[21]  F H Hausheer,et al.  Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[23]  Jiunn H. Lin,et al.  Role of P-Glycoprotein in Pharmacokinetics , 2003, Clinical pharmacokinetics.

[24]  A. Nomeir,et al.  Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. , 2001, International journal of pharmaceutics.

[25]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[26]  B. Rothen‐Rutishauser,et al.  Cell cultures as tools in biopharmacy. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  S. Chong,et al.  In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of in Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System , 2004, Pharmaceutical Research.

[28]  P. Augustijns,et al.  Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. , 2003, Journal of pharmaceutical sciences.

[29]  W. Sadee,et al.  Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[31]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[33]  T. Uchiumi,et al.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.

[34]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[35]  Lawrence X. Yu,et al.  Effect of common excipients on Caco-2 transport of low-permeability drugs. , 2001, Journal of pharmaceutical sciences.

[36]  A. Avdeef,et al.  PAMPA--a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA models. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  Joseph W. Polli,et al.  Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor , 1999, Pharmaceutical Research.

[38]  I. Hidalgo,et al.  Assessing the absorption of new pharmaceuticals. , 2001, Current topics in medicinal chemistry.

[39]  S. Chong,et al.  Cell culture-based models for intestinal permeability: a critique. , 2005, Drug discovery today.

[40]  W. Rubas,et al.  Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. , 1996, Journal of pharmaceutical sciences.

[41]  K. Hillgren,et al.  In vitro systems for studying intestinal drug absorption , 1995, Medicinal research reviews.

[42]  Li Di,et al.  Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. , 2004, Journal of pharmaceutical sciences.

[43]  D. Greenblatt,et al.  Rapid Assessment of P-Glycoprotein Inhibition and Induction in Vitro , 2003, Pharmaceutical Research.

[44]  B. Jarvis,et al.  Fexofenadine , 2000, Drugs.

[45]  J. Dressman,et al.  Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women , 1993, Pharmaceutical Research.

[46]  Pratik Saha,et al.  Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[47]  A. Florence,et al.  Effects of Some Non‐ionic Surfactants on Transepithelial Permeability in Caco‐2 Cells , 2000, The Journal of pharmacy and pharmacology.

[48]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[49]  Y. Sawada,et al.  Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. , 1992, Journal of hepatology.

[50]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[51]  R. Borchardt,et al.  Isolation and Characterization of Caco-2 Subclones Expressing High Levels of Multidrug Resistance Protein Efflux Transporter , 2003, Pharmaceutical Research.

[52]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.